February 02, 2015
January 16, 2015
December 23, 2014
A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.
EntreMed leverages best of China and the West and seeks to expand pipeline.
Phase II Study of Oral ENMD-2076 Administered to Patients (pts) With Advanced Soft Tissue Sarcoma
Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinoma